tbuckley/cabot-search huggingface dataset:
ACTR-33. INFIGRATINIB (BGJ398) IN PATIENTS WITH RECURRENT GLIOMAS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) ALTERATIONS: A MULTICENTER PHASE II STUDY
Authors: Andrew Lassman, Juan Sepúlveda-Sánchez, Timothy Cloughesy, Juan Gil-Gil, Vinay Puduvalli, Jeffrey Raizer, Filip De Vos, Patrick Wen, Nicholas Butowski, Paul Clement, Morris Groves, Cristobal Belda-Iniesta, Keith Steward, Steven Rowsey, Yining Ye, Patrick Roth
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION FGFR mutations and translocations occur in approximately 10% of glioblastomas (GBMs). FGFR3-TACC3 fusion is predictive of response to FGFR tyrosine kinase inhibitors pre-clinically and clinically. Infigratinib (BGJ398) is a selective small-molecule pan-FGFR kinase inhibitor with anti-tumor activity in several solid tumors with FGFR genetic alterations. METHODS Open-label phase II trial of adults with recurrent high-grade gliomas following failure of initial therapy (NCT01975701). Tumors harbored FGFR1-TACC1 or FGFR3-TACC3 fusions, activating mutations in FGFR1, 2 or 3, or FGFR1, 2, 3, or 4 amplification. Oral infigratinib was administered 125 mg d1–21 q28d. Prophylaxis for hyperphosphatemia was recommended. Primary endpoint: 6-month progression-free survival (6mPFS) rate by RANO (locally assessed); goal of &gt;40%. RESULTS As of Sep 2017, 26 patients (16 men, 10 women; median age 55 years, range 20–76 years; 50% with ≥ 2 prior regimens) were treated; 24 (92.3%) discontinued for disease progression (n=21) or other reasons (n=3). All had FGFR1 or FGFR3 gene alterations; 4 had &gt;1 gene alteration. Estimated 6mPFS rate was 16% (95% CI 5.0–32.5%); median PFS was 1.7 months (95% CI 1.1–2.8 months); median OS was 6.7 months (95% CI 4.2–11.7 months); ORR was 7.7% (95% CI 1.0–25.1%). Best overall response was: partial response 7.7% (FGFR1 mutation n=1; FGFR3 amplification n=1); stable disease 26.9%; progressive disease 50.0%; missing/unknown 15.3%. Most common (&gt;15%) all-grade treatment-related adverse events (AEs) were hyperphosphatemia, fatigue, diarrhea, hyperlipasemia, and stomatitis. There were no grade 4 treatment-related AEs. Eleven patients (42.3%) had treatment-related AEs requiring dose interruptions/reductions (most commonly hyperphosphatemia). CONCLUSIONS Infigratinib induced partial response or stable disease in approximately one-third of patients with recurrent GBM and/or other glioma subtypes harboring FGFR alterations. Most AEs were reversible and manageable. Further potential combinations are being explored in patients with proven FGFR-TACC fusion genes; analysis of biomarker data is ongoing.
THROMBALLOSIS.
Authors: GEO. N. MONETTE
Journal: JAMA (1884)

The phenomena typical of thromballosis (and embolism), in contradistinction to apoplexy, coincident with rupture of a cerebral vessel, are of a more pronounced and complicated character than those of apoplexy. Although apoplexy, in the aged, may be more rapidly fatal, yet an embolism may complicate with diversified phenomena, and the patient may linger for a long time. The differentiating feature being that fatal, embolic cases the pressure upon brain tissue is from within outwards, but circumscribed by the limits of the dilated vessel, and not diffused over the adjacent tissue, similar to extra-vascular, as occurs when rupture of vessel takes place, thereby causing extensive circumjacent pressure and obliteration of cerebral function; often profound coma, or bona-fide apoplexy is caused. We know that the predisposing cause of apoplexy is an atheromatous degeneration of the internal coat of arteries, vice-versa, in thromballosis the pathology is induced by an endarteritis or phlebitis, yet
Coordinated effort to fight breast cancer begins
Authors: C. Marwick
Journal: JAMA (1994)

THE EFFORT to get all the forces working on breast cancer to march forward in some coordinated manner has begun. Donna E. Shalala, PhD, director of the Department of Health and Human Services (HHS), says such concerted effort is necessary to make sure that all the efforts currently devoted to breast cancer—research, treatment, prevention, education, and access—are on track. Shalala spoke at a day-long breast cancer planning conference held at the National Institutes of Health (NIH), Bethesda, Md, at which the planners were charged with identifying priorities in fighting the disease. The HHS called on a broad spectrum of individuals, including scientists, health care providers, representatives from private industry, and consumer groups, to pull together what Shalala calls "an action plan on breast cancer." The attempt to coordinate efforts to deal definitively with breast cancer has its roots in the burgeoning interest in women's health, which was addressed in the
Metered-Dose Inhalers: Drug Delivery Over the Life of a Canister
Authors: William Weiss
Journal: JAMA (1993)

<h3>To the Editor.</h3> —In a recent letter, Bergner et al<sup>1</sup>called attention to a problem in the use of metered-dose inhalers (MDIs) in the treatment of asthma: some exacerbations occur when patients use MDIs beyond the number of sprays specified by the manufacturer. A related problem can occur when the dose per spray specified by the manufacturer actually delivered declines substantially before the specified number of inhalations is reached. Being retired, I can only provide evidence of this phenomenon from my own personal experience. I have been using flunisolide inhalations (AeroBid with the company's spacer, Forest Pharmaceuticals Inc, St Louis, Mo) for the treatment of cough-variant asthma since 1990, using the company's directions. My dose has always been two inhalations twice a day and this is very effective in the control of my symptoms. However, after the 17th day of use I found that the strength of the spray declined
Consequences of climate change.
Journal: Environmental Health Perspectives (1995)

Forum cial component of the mammalian cell- death pathway."It is something that we suspect will be activated in a variety of dif- ferent instances of apoptosis," Tewari said.Apoptosis is a sequential, programmed series of steps by which cells destroy themselves.Some scientists suggest that inappro- priate apoptosis may be responsible for damage seen in autoimmune disorders, immune deficiencies, Alzheimer's, Hunt- ington's and Parkinson's diseases, cancers, stroke, and heart attack.The recent discovery was made using mammalian systems.It underscores the sim- ilarities between apoptosis in the nematode worm, Caenorhabditis elegant (which has provided much of our understanding about apoptosis) and mammals.In the nematode, apoptosis is controlled by sets of genes including ced-3 and ced-9.Expression of ced-3 is required for cell death to occur.Expression of ced-9 blocks cell death.The
Influenza: Prospects for Control
Authors: Joseph J. Mazza, Steven H. Yale
Journal: Annals of Internal Medicine (2002)

Letters19 February 2002Influenza: Prospects for ControlJoseph J. Mazza, MD and Steven H. Yale, MDJoseph J. Mazza, MDMarshfield Clinic; Marshfield, WI 54449Search for more papers by this author and Steven H. Yale, MDMarshfield Clinic; Marshfield, WI 54449Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-4-200202190-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read Couch's editorial on influenza (1) with interest. After extensively reviewing the literature and searching specifically for the efficacy of the influenza vaccine and the true incidence of influenza virus infection, we were struck by the lack of evidence-based data to support the current perceived status of annual influenza immunization and its impact on the incidence of influenza. Every fall, health care providers are bombarded by patients and the news media about the upcoming “flu season” and the status of the new vaccine. Yet, in most of the randomized studies we reviewed, the end points and ...References1. Couch RB. Influenza: prospects for control. Ann Intern Med. 2000;133:992-8. [PMID: 11119401] LinkGoogle Scholar2. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994;331:778-84. [PMID: 8065407] CrossrefMedlineGoogle Scholar3. Potter J, Stott DJ, Roberts MA, Elder AG, O'Donnell B, Knight PV, et al . Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis. 1997;175:1-6. [PMID: 8985189] CrossrefMedlineGoogle Scholar4. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 1999;130:397-403. [PMID: 10068413] LinkGoogle Scholar5. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994;272:1661-5. [PMID: 7966893] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Marshfield Clinic; Marshfield, WI 54449 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoInfluenza: Prospects for Control Robert B. Couch Influenza: Prospects for Control Robert B. Couch Metrics 19 February 2002Volume 136, Issue 4Page: 338KeywordsFallsFeversHealth care providersHospitalizationsLaboratory testsMortalityPharyngitisRespiratory systemUpper respiratory tract infectionsVaccines ePublished: 19 February 2002 Issue Published: 19 February 2002 CopyrightCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Vaccination-Associated relapse of immune thrombocytopenia
Authors: J. G. Kelton
Journal: JAMA (1981)

Many patients with immune thrombocytopenia require splenectomy to achieve remission. They are therefore at risk for postsplenectomy septicemia and should receive vaccination against<i>Streptococcus pneumoniae</i>. In experiment situations, antigens contained within this vaccine can initiate a polyclonal B-lymphocyte activation and increased production of specific and nonspecific antibodies. In certain animal models, a polyclonal B-lymphocyte stimulatory response can trigger an autoimmune disorder. Two patients with immune thrombocytopenia had relapses of their immune thrombocytopenia after the administration of pneumococcal and influenza vaccines. These observations suggest that patients with a history of immune thrombocytopenia should be monitored after vaccination. (<i>JAMA</i>1981;245:369-371)
THE APPLICATION OF A NEW METHOD OF RESEARCH.
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Drowning
Authors: Tim Driscoll
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE METABOLISM OF NERVES
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Calcium antagonists: long-awaited new therapy for heart disease
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical News
Journal: JAMA (1924)

(Physicians will confer a favor by sending for this department items of news of more or less genERAL interest: SUCH AS RELATE to SOCIETY activities, new HOSPITALS, EDUCATION, PUBLIC health, ETC.) <h3>CALIFORNIA</h3><h3>Chiropractor Held.</h3> —According to reports, W. E. Purviance, chiropractor of Los Angeles, was recently arrested on a statutory charge, preferred by the mother of Mary Schwaln. <h3>Hospital Association Organized.</h3> —The San Francisco Bay Counties Hospital Association was organized, December 6, in San Francisco, with Dr. Lionel S. Schmitt, director of hospitals, University of California, as president, and Dr. Attilio S. Musante of St. Joseph's Hospital, temporary secretary. <h3>Society for Blind Organized.</h3> —The California Society for the Blind was organized, Nov. 8, 1923, with Dr. Edward F. Glaser as president. The immediate projects of the society are: the organization of a campaign for the prevention of blindness; the establishment of a nursery and kindergarten for blind children of preschool
HIV Drug Resistance
Authors: F. Clavel
Journal: New England Journal of Medicine (2004)

Combinations of antiretroviral drugs have proven remarkably effective in controlling the progression of HIV disease and prolonging survival, but these benefits can be compromised by the development of drug resistance. About 50 percent of patients receiving antiretroviral therapy in the United States are estimated to harbor viruses that express resistance to at least one of the available antiretroviral drugs.
Signs and symptoms
Authors: L. S. King
Journal: JAMA (1968)

Most physicians, if asked to distinguish between signs and symptoms, would reply in a fashion something like this: A<i>symptom</i>is a manifestation of disease apparent to the patient himself, while a<i>sign</i>is a manifestation of disease that the physician perceives. The sign is objective evidence of disease; a symptom, subjective. Symptoms represent the complaints of the patient, and if severe, they drive him to the doctor's office. If not severe, they may come to light only after suitable questions. The patient perceives, for example, subjective pains and discomforts [Doctor, I have a bad headache], or disturbances of function [Doctor, I can't move my arm the way I used to], or some simple appearance [Doctor, I have had this rash for the past ten days and I'm worried about it]. But the physician, as a skilled observer, can discern what the patient cannot. He can look, palpate and percuss,
Physician's Assistant or Assistant Physician?
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recurrent Mononucleosis
Authors: Alfred S. Evans
Journal: JAMA (1963)

<h3>To the Editor:</h3> —A paper and an editorial on infectious mononucleosis appeared in the Dec 1 issue ofThe Journal(<b>182</b>:955 &amp; 939, 1962), both of which stressed the need for basing diagnosis on clinical, hematological, and serological changes. They point out that the purported protean manifestations of the disease are based largely on reports of atypical cases in which these criteria are not fully met. I agree with the need for rigid diagnostic standards when including atypical cases in the category of infectious mononucleosis. Indeed, I would add changes in the cephalin flocculation test as an additional criterion for diagnosis. On the other hand, the arbitrary nature of such criteria should be fully recognized. Almost all university students we see in the infirmary have limited patterns of symptomatology and rarely what could be called unusual or protean manifestations. Nevertheless, not all such characteristic patients have increased heterophil antibodies.
Malignant melanoma
Authors: S. Ivaz, H. Lloyd-Hughes, P. Oakeshott, S. Shah
Journal: BMJ (2009)

A 40 year old white woman is worried about a 5 × 7 mm brown and black lesion on her arm that has been getting darker over the past few months and has begun to itch. It has a regular border but is slightly raised. She has no axillary lymphadenopathy.
Die Krebskrankheit.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Relation of Osteopenia to Glucocorticoid Replacement Therapy in Addison Disease
Authors: Peter M. J. Jellison
Journal: Annals of Internal Medicine (1994)

Letters1 August 1994Relation of Osteopenia to Glucocorticoid Replacement Therapy in Addison DiseasePeter M. J. Jellison, MD and Ronald J. M. Croughs, MDPeter M. J. Jellison, MDSearch for more papers by this author and Ronald J. M. Croughs, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-121-3-199408010-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Devogelaer and associates fail to recognize our main findings: 1) an inverse correlation between hydrocortisone dose per kg of body weight and bone mineral density [BMD] of the lumbar spine in men receiving long-term, conventional glucocorticoid replacement therapy for Addison disease and 2) the decreased BMD in 30% of these patients associated with use of a relatively high dose of hydrocortisone per kg of body weight. The inevitable conclusion is that conventional glucocorticoid replacement therapy induces chronic, mild oversubstitution; the title of our article is therefore correct. The effects of glucocorticoid treatment on statural growth in children with ... Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1994Volume 121, Issue 3Page: 235-237KeywordsAndrogensBlood plasmaBody weightBone mineral densityBone resorptionGlucocorticoid therapySodiumSpineThyroidThyroid-stimulating hormone ePublished: 15 August 2000 Issue Published: 1 August 1994 Copyright & PermissionsCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...